Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Mesoblast Limited (MESO) Price & Performance

iShares JPMorgan USD Emerging Markets Bond ETFTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

iShares JPMorgan USD Emerging Markets Bond ETF vs Mesoblast Limited — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $94.83, while Mesoblast Limited trades at $16.68 (market cap $2.16B). Which is the better fit depends on your goals.

EMBMESO
Sector
Fixed IncomeTechnology
52-Week High
$97.74$20.96
52-Week Low
$92.95$12.88
Market Cap
$2.16B
Enterprise Value
$2.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares JPMorgan USD Emerging Markets Bond ETF

EMB, the iShares J.P. Morgan USD Emerging Markets Bond ETF, trades at $95.24, up 0.31% over 24 hours. Technical indicators are mixed, with a neutral overall signal and bearish moving averages. Recent dividend distributions provide income, but key financial ratios are unavailable. News sentiment highlights yield-driven returns amid emerging market sovereign risks.

Outlook hinges on income from its 5.1% yield, with limited price upside expected. Risks include emerging market defaults and Federal Reserve policy shifts. Analysts rate it a hold, emphasizing diversification benefits but cautioning on macro triggers.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

About iShares JPMorgan USD Emerging Markets Bond ETF

EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.

Read more on EMB

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO